Hoechst reportedly stalls RU-486 in U.S.
D000288:Administrative Personnel; D000569:Americas; D001695:Biology; D003132:Commerce; D003257:Consumer Product Safety; D003267:Contraception; D019049:Developed Countries; D004467:Economics; D004703:Endocrine System; D005193:Family Planning Services; D006076:Government; D006297:Health Services Accessibility; D006727:Hormone Antagonists; D006728:Hormones; D007878:Legislation as Topic; D015735:Mifepristone; D009656:North America; D010827:Physiology; D011057:Politics; D014481:United States
D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone
Administrative Personnel; Americas; Biology; Commerce; Commercial Sector; Contraception; Contraceptive Availability; Developed Countries; Economic Factors; Endocrine System; Family Planning; Government Officials; Hormone Antagonists; Hormones; Legislation; Macroeconomic Factors; North America; Northern America; Physiology; Policymakers; Political Factors; Product Approval; Ru-486; United States